Ptc Therapeutics PTCT
NASDAQ PTCT
$63.04 +0.42 (+0.67%)
At close: Oct 22, 2026 · 4:00 PM EDT

Ptc Therapeutics (PTCT) Preferred Stock Liabilities (2012)

Updated

Ptc Therapeutics (PTCT) recorded Preferred Stock Liabilities of $80.82 million in Q4 2012.

Analysis

Ptc Therapeutics (PTCT) Preferred Stock Liabilities (2012) Analysis & Trends

  • Across earlier years, Preferred Stock Liabilities came in at $214.38 million in FY2011.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Eli Lilly 1,165.22 Bn 1,133.81 Bn 19.71 Bn -
2 Johnson & Johnson 646.28 Bn 566.14 Bn 17.30 Bn -
3 AbbVie 503.17 Bn 476.28 Bn 12.70 Bn -
4 Merck 365.23 Bn 319.60 Bn 12.21 Bn -
5 Novartis Ag 302.66 Bn 266.65 Bn 11.24 Bn -
6 Astrazeneca 267.39 Bn 241.08 Bn 12.86 Bn -
7 Amgen 241.61 Bn 197.01 Bn 7.24 Bn -
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn -
9 Pfizer 172.91 Bn 119.55 Bn 10.94 Bn -
10 Ptc Therapeutics 5.22 Bn -2.54 Bn 340.60 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2012 80.82 Mn
API Access

Ptc Therapeutics Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=PTCT&period=max&api_key=YOUR_API_KEY